Polypeptide growth factors: Targeted delivery systems

Biomaterials

Volumn 18, Issue 18, 1997, Pages 1201-1225

  Nimni, M E ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

BMPs; Growth factors; Targeted delivery; TGF

Indexed keywords

CELLS; DRUG DOSAGE; DRUG PRODUCTS; DRUG THERAPY;

GROWTH FACTORS; TARGETED DELIVERY; TISSUE REPAIR; WOUND HEALING;

POLYPEPTIDES;

BONE MORPHOGENETIC PROTEIN; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; POLYPEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; HUMAN; PRIORITY JOURNAL; REVIEW; TISSUE REPAIR; WOUND HEALING;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIOMEDICAL ENGINEERING; BONE MORPHOGENETIC PROTEINS; CICATRIX, HYPERTROPHIC; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FRACTURE HEALING; GROWTH SUBSTANCES; HUMANS; KELOID; NERVE GROWTH FACTORS; PEPTIDES; PLATELET-DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 0030753482     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(97)00050-1     Document Type: Review

References (228)

1. 1. McKay, I.A., In Growth Factors: A Practical Approach, ed. I.A. McKay and I. Leigh. IRL Press, Oxford, 1993, p. 251.
2. 2. Sporn, M.B. and Todaro, G.J., Autocrine secretion and malignant transformation of cells. New Engl. J. Med., 1980, 303, 878-880.
3. 3. Massague, J., Transforming growth factor-alpha. A model for membrane-anchored growth factors. J. Biol. Chem., 1990, 265, 21393-21396.
4. 4. Re, R.N., The cellular biology of angiotensin: paracrine, autocrine and intracrine actions in cardiovascular tissues. J. Molec. Cell. Cardiol., 1989, 21, 63-69.
5. 5. Parker, T.G. and Schneider, M.D., Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. Annu. Rev. Physiol., 1991, 53, 179-200.
6. 6. Florini, J.R., Ewton, D.Z. and Magri, K.A., Hormones, growth factors, and myogenic differentiation. Annu. Rev. Physiol., 1991, 53, 201-216.
7. 7. Canalis, E., McCarthy, T.L. and Centrell, M., Growth factors and cytokines in bone cell metabolism. Annu. Rev. Med., 1991, 42, 17-24.
8. 8. Bowen-Pope, D.F., Malpass, T.W., Foster, D.M. and Ross, R., Platelet-derived growth factor in vivo: levels, activity, and rate of clearance. Blood, 1984, 64, 458-469.
9. 9. Wakefield, L.M., Winoker, T.S., Hollands, R.S., Christopherson, K., Levinson, A.D. and Sporn, M.B., Recombinant latent TGF-β1 has a longer half life in rats than active TGF-β1 and a different tissue distribution. J. Clin. Invest., 1991, 86, 1976-1984.
10. 10. Skalak, R. and Fox, C.F. (eds), Tissue Engineering. Liss, New York, 1988.
11. 11. Langer, R. and Vacanti, J.P., Tissue engineering. Science, 1993, 260, 920-926.
12. 12. Massague, J., The transforming growth factor-β family. Annu. Rev. Cell Biol., 1990, 6, 597-641.
13. 13. Roberts, A.B. and Sporn, M.B., The transforming growth factor-βs. Handbook Exp. Pharmacol., 1990, 95/I, 419-472.
14. 14. Attisano, L., Wrana, J.L. and Massague, J., TGF-β receptors and actions. Biochim. Biophys. Acta, 1994, 1222, 71-80.
15. 15. Roberts, A.B. and Sporn, M.B., Physiological action and clinical applications of transforming growth factor-β. Growth Factor, 1993, 8, 1-9.
16. 16. Flaumenhaft, R., Abe, M., Miyazono, K., Harpel, J.G., Heldin, C.H. and Rifkin, D.B., Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J. Cell Biol., 1993, 120, 995-1002.
17. 17. Miyazono, K. and Heldin, C.H., Role of carbohydrate structure in TGF-β latency. Nature, 1989, 338, 158-160.
18. 18. Sato, A. and Rifkin, D.B., Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor β-1-like molecule by plasmin during co-culture. J. Cell Biol., 1989, 109, 309-315.
19. 19. Taipale, J., Miyazono, K., Heldin, C. and Keski, O.J., Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein. J. Cell Biol., 1994, 124, 171-181.
20. 20. Kojima, S. and Rifkin, D.B., Mechanism of retinoid-induced activation of latent transforming growth factor-β in bovine endothelial cells. J. Cell Physiol., 1993, 155, 323-332.
21. 21. Bendixen, E., Borth, W. and Harpel, P.C., Crosslinking of plasminogens to fibronectin by factor XIIIa and tissue transglutaminase. Blood, 1991, 78 (Suppl.), 1-28.
22. 22. Schultz-Cherry, S., Ribeiro, S., Gentry, L. and Murphy, U.J., Thrombospondin binds and activates the small and large forms of latent transforming growth factor-β in a chemically defined system. J. Biol. Chem., 1994, 269, 26775-26782.
23. 23. Schultz-Cherry, S., Lawler, J. and Murphy-Ulrich, J., The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-β. J. Biol. Chem., 1994, 269, 26783-26788.
24. 24. Miyazono, K. and Heldin, C.H., Latent forms of TGF-β: molecular structure and mechanisms of activation. In Clinical Applications of TGF-β, CIBA Foundation Symp. 157. John Wiley, Chichester, 1991, pp. 81-90.
25. 25. Oreffo, R.O., Mundy, G.R., Seyedin, S.M. and Bonewald, L.F., Activation of the bone-derived latent TGF-beta complex by isolated osteoclasts. Biochem. Biophys. Res. Commun., 1989, 158, 817-823.
26. 26. Antonelli-Orlidge, A., Saunders, K.B., Smith, S.R. and D'Amore, P.A., An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes. Proc. Natl. Acad. Sci. USA, 1989, 86, 4544-4548.
27. 27. Olofsson, A., Miyazono, K., Kanzaki, T., Colosetti, P., Engstrom, U. and Heldin, C.H., Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J. Biol. Chem., 1992, 267, 19482-19488.
28. 28. Pelton, R.W., Johnson, M.D., Perkett, E.A., Gold, L.I. and Moses, H.L., Expression of transforming growth factor-beta 1, -beta 2, and -beta 3 mRNA and protein in the murine lung. Am. J. Respir. Cell Molec. Biol., 1991, 5, 522-530.
29. 29. Butzow, R., Fukushima, D., Twardzik, D.R. and Ruoslahti, E., A 60-kD protein mediates the binding of transforming growth factor-β to cell surface and extracellular matrix proteoglycans. J. Cell Biol., 1993, 122, 721-727.
30. 30. McCaffrey, T.A., Falcone, D.J. and Du, B., Transforming growth factor-β1 is a heparin-binding protein: identification of putative heparin-binding region and isolation of heparins with varying affinity for TGF-β1. J. Cell Physiol., 1992, 152, 430-440.
31. 31. McCaffrey, T.A., Falcone, D.J., Vicente, D., Du, B., Consigli, S. and Borth, W., Protection of transforming growth factor-β1 activity by heparin and fucoidan. J. Cell Physiol., 1994, 159, 51-59.
32. 32. Yamaguchi, Y., Mann, D.M. and Ruoslahti, E., Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature, 1990, 346, 281-284.
33. 33. Border, W.A., Boble, N.A., Yamamoto, T. et al., Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature, 1992, 360, 361-364.
34. 34. Lopez, C.F., Payne, H.M., Andres, J.L. and Massague, J., Betaglycan can act as a fuel modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J. Cell Biol., 1994, 124, 557-568.
35. 35. Keski-Oja, J., Lohi, K. and Laiho, M., Growth factors in the regulation of plasminogen-plasmin system in tumor cells. Semin. Thromb. Hemostas., 1991, 17, 231-239.
36. 36. Attisano, L., Wrana, J., Lopez, C.F. and Massague, J., TGF-β receptors and action. Biochim. Biophys. Acta, 1994, 1222, 71-80.
37. 37. Lopez, C.F., Cheifetz, J.D., Andres, J.L., Lane, W. and Massague, J., Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system. Cell, 1991, 67, 785-795.
38. 38. Border, W.A. and Ruoslahti, E., Transforming growth factor-β in disease: the dark side of tissue repair. J. Clin. Invest., 1992, 90, 1-7.
39. 39. Border, W.A. and Noble, N.A., Transforming growth factor β in tissue fibrosis. New Engl. J. Med., 1994, 331(19), 1994, 1286-1292.
40. 40. Mustoe, T.A., Pierce, G.F., Thomason, A., Gramates, P., Sporn, M.B. and Deuel, T.F., Accelerated healing of incisional wounds in rats induced by transforming growth factor-β. Science, 1987, 237, 1333-1336.
41. 41. Beck, L.S., DeGuzman, L., Lee, W.P., Xu, Y., Siegel, M.W. and Amento, E.P., One systemic administration of transforming growth factor-β1 reverses age-or glucocorticoid-impaired wound healing. J. Clin. Invest., 1993, 92, 2841-2849.
42. 42. Sporn, M.B. and Roberts, A.B., A major advance in the use of growth factors to enhance wound healing. J. Clin. Invest., 1993, 92, 2565-2566.
43. 43. Terrel, T.G., Working, P.K., Chow, C.P. and Green, J.D., Pathology of recombinant human transforming growth factor-β1 in rats and rabbits. Int. Rev. Exp. Pathol., 1993, 34, 43-67.
44. 44. Tredget, E.E., The molecular biology of fibroproliferative disorders of the skin: potential cytokine therapeutics. Ann. Plast. Surg., 1994, 33, 152-154.
45. 45. Younai, S., Venter, G., Vu, S., Nichter, L., Nimni, M.E. and Tuan, T.-L., Role of growth factors in scar contraction: an in vitro analysis. Ann. Plast. Surg., 1996, 36, 495-501.
46. 46. , Younai, S., Nichter, L.S., Wellisz, T., Reinisch, J., Nimni, M.E. and Tuan, T.-L., Modulation of collagen synthesis by TGF-β in keloid and hypertrophic scar fibroblasts. Ann. Plast. Surg., 1994, 33, 148-151.
47. 47. Seyedin, S.M., Thompson, A.Y., Bentz, H. et al., Cartilage-inducing factor A. Apparent identity to transforming growth factor β. J. Biol. Chem., 1986, 261(13), 5693-5695.
48. 48. Centrella, M., Massague, J. and Canalis, E., Human platelet-derived transforming growth factor β stimulates parameters of bone growth in fetal rat calvaria. Endocrinology, 1986, 119, 2306-2312.
49. 49. Noda, M. and Camilliere, J.J., In vivo stimulation of bone formation by transforming growth factor-β. Endocrinology, 1989, 124, 2991-2994.
50. 50. Strates, B.S., Kilaghbran, V., Nimni, M.E. and McGuire, M.H., Enhanced periosteal osteogenesis induced by rTGF-β1 adsorbed on microcrystals of hydroxyapatite. Trans. Orthop. Res. Soc., 1992, 591.
51. 1 induces bone closure of skull defects. J. Bone Min. Res., 1991, 6, 1257-1265.
52. 52. Strates, B.S. and Connolly, J.F., Osteogenesis in cranial defects and diffusion chambers. Acta Orthop. Scand., 1980, 60(2), 200-203.
53. 53. Gombotz, W.R., Pankey, S.C., Bouchard, L.S., Ranchalis, J. and Puolakkainen, P., Controlled release of TGF-β1 from a biodegradable matrix for bone regneration. J. Biomater. Sci., Polym. Edn, 1993, 5(1/ 2), 49-63.
54. 54. Dibiase, M.D. and Rhodes, C.T., The design of analytical methods for use in topical epidermal growth factor product development. J. Pharm. Pharmacol., 1991, 43, 553-558.
55. 55. Brown, L.G., Nanney, L.B., Griffen, J. et al., Enhancement of wound healing by topical treatment with epidermal growth factor. New Engl. J. Med., 1989, 321, 76-79.
56. 56. Brown, G.L., Curtsinger, L.J., White, M. et al., Acceleration of tensile strength of incisions treated with EGF and TGF-β. Ann. Surg., 1988, 208, 788-794.
57. 57. Jyung, R.W. and Mustoe, T.A., Role of cytokines in wound repair. In Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis, and Therapy, ed. A. Gearing et al. Oxford University Press, 1992, pp. 307-328.
58. 131I conjugates on the clonogenic survival of cultured glioma cells. J. Neuro-Oncol., 1992, 14, 213-223.
59. 59. Celebi, N., Erden, N., Gonul, B. and Koz, M., Effects of epidermal growth factor dosage forms on dermal wound strength in mice. J. Pharm. Pharmacol., 1994, 46, 386-387.
60. 60. Chen, J., Gamou, S., Takayanagi, A. and Shimizu, N., A novel gene delivery system using EGF receptor-mediated endocytosis. FEBS Lett., 1994, 33, 167-169.
61. 61. Hirota, N., Ueda, M., Ozawa, S., Abe, O. and Shimizu, N., Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res., 1989, 49, 7106-7109.
62. 62. Wu, G.Y. and Wu, C.H., Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem., 1987, 262, 4429-4432.
63. 63. Buckley, A., Davidson, J.M., Kamerath, C.D. and Woodward, S.C., Epidermal growth factor increases granulation tissue formation dose dependency. J. Surg. Res., 1987, 43, 322-328.
64. 64. Grotendorst, G.R., Soma, Y., Takehara, K. and Charette, M., EGF and TGF-α are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J. Cell Physiol., 1989, 139, 617-623.
65. 65. Nanney, L.B., King, L.E. and Stoscheck, C., Quantitative determination of EGF receptors during murine epidermal repair (abstract). The Wound Healing Society, 1st Annual Scientific Meeting, 1991.
66. 66. Buckley, A., Davidson, J.M., Kamerath, C.D., Wolt, T.B. and Woodward, S.C., Sustained release of epidermal growth factor accelerates wound repair. Proc. Natl. Acad. Sci. USA, 1985, 82, 7340-7344.
67. 67. Davidson, J., Buckley, A., Woodward, S., Nichols, W., McGee, G. and Demetriao, A., Mechanisms of accelerated wound repair using epidermal growth factor and basic fibroblast growth factor. In Growth Factors and Other Aspects of Wound Healing: Biological and Clinical Applications, ed. A. Barbul, E. Pines, M. Caldwell and T.K. Hunt. Alan R. Liss, New York, 1988, pp. 63-75.
68. 68. Hennessey, P.J., Black, C.T. and Andrassy, R.J., Epidermal growth factor and insulin act synergistically during diabetic healing. Arch. Surg., 1990, 125, 926-929.
69. 69. Laato, M., Heino, J., Kahari, V.-M., Ninikoski, J. and Vuorio, E., Epidermal growth factor increases collagen production in granulation tissue by stimulation of fibroblast proliferation and not by activation of procollagen genes. Biochem. J., 1987, 247, 385-388.
70. 70. Lawrence, W.T., Sporn, M.B., Gorsohboth, C., Norton, J.A. and Grotendorst, G.R., The reversal of an adriamyain-induced healing impairment with chemoattractants and growth factors. Ann. Surg., 1986, 203, 142-147.
71. 71. Brewitt, B. and Clark, J.I., A new method for study of normal lens development in vitro using pulsatile delivery of PDGF or EGF in HL-1 serum-free medium. Cell. Dev. Biol., 1990, 26, 305-314.
72. 72. Kingsworth, A.N., Vowles, R. and Nash, J.R.G., Epidermal growth factor increases tensile strength in intestinal wounds in pigs. Br. J. Surg., 1990, 77, 409-412.
73. 73. Brown, G.L., Curtsinger, L.J., White, M. et al., Acceleration of tensile strength of incisions treated with EGF and TGF-β. Ann. Surg., 1988, 208, 788-794.
74. 74. Brightwell, J.R., Riddle, S.L., Eiferman, R.A. et al., Biosynthetic human EGF accelerates healing of neodecadron-treated primate corneas. Invest. Ophthalmol. Vis. Sci., 1985, 26, 105-110.
75. 75. Calel, B. and Fagerholm, P., Human epidermal growth factor - the influence on healing of surgically closed corneal wounds. Acta Ophthalmol. (Copenh.), 1987, 65, Suppl. 182, 65,58-61.
76. 76. Leibowitz, H.M., Morello, S., Stern, M. and Kupperman, A., Effect of topically administered epidermal growth factor on corneal wound strength. Arch. Ophthalmol., 1990, 108, 734-737.
77. 77. Mathers, W.D., Sherman, M., Fryczkowski, A. and Jester, J.V., Dose-dependent effects of epidermal growth factor on corneal wound healing. Invest. Ophthalmol. Vis. Sci., 1989, 30, 2403-2406.
78. 78. Petroutsos, G., Courty, J., Guimaraes, R. et al., Comparison of the effects of EGF, bFGF, and EDGF on corneal epithelial wound healing. Curr. Eye Res., 1984, 3, 593-598.
79. 79. Woost, P.G., Brightwell, J., Eiferman, R.A. and Schultz, G.S., Effect of growth factors with dexamethasone on healing of rabbit corneal stromal incisions. Exp. Eye Res., 1985, 40, 47-60.
80. 80. Greene, L.A. and Shooter, E.M., The nerve growth factor: biochemistry, synthesis, and mechanism of action. Annu. Rev. Neurosci., 1980, 3, 353-402.
81. 81. Hamburger, V., Trophic interactions in neurogenesis: a personal historical account. Annu. Rev. Neurosci., 1980, 3, 269-278.
82. 82. Pintar, J.E., Structure and expression of the nerve growth factor gene. In Oncogenes, Genes, and Growth Factors, ed. G. Guroff. John Wiley, New York, 1987, pp. 103-131.
83. 83. Hoffman, D., Breakefield, O.X., Short, M.P. and Aebischer, P., Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Exp. Neurol., 1993, 122, 100-106.
84. 84. Allen, G.S., Burns, R.S., Tulipen, N.B. and Parker, R.A., Adrenal medullary transplantation to the caudate nucleus in Parkinson's disease. Initial clinical results in 18 patients. Arch. Neurol., 1989, 46, 487-491.
85. 85. Dubach, M., Schmidt, R.H., Martin, R., German, D.C. and Bowden, D.M., Transplant improves hemiparkinsonian syndrome in non-human primate: intracerebral injection, rotometry, tyrosine hydroxylase immunohistochemistry. Prog. Brain Res., 1988, 78, 491-496.
86. 86. Low, W.C., Triarhou, L.C., Kaseda, Y., Norton, J. and Ghetti, B., Functional innervation of the striatum by ventral mesencephalic grafts in mice with inherited nigrostriatal dopamine deficiency. Brain Res., 1987, 435, 315-321.
87. 87. Strecker, R.E., Sharp, T., Brundin, P., Zetterstrom, T., Ungerstedt, U. and Bjorklund, A., Autoregulation of dopamine release and metabolism by instrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience, 1987, 22, 169-178.
88. 88. Stromberg, I., Herrera-Marschitz, M., Ungerstedt, U., Ebendal, T. and Olson, L., Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behavior. Exp. Brain Res., 1985, 60, 335-349.
89. 89. McRae-Degueurce, A., Hjorth, S., Dillon, D., Mason, D.W. and Rice, T.R., Implantable microencapsulated dopamine (DA): a new approach for slow-release DA delivery into brain tissue. Neurosci. Lett., 1988, 92, 303-309.
90. 90. Maysinger, D., Jalsenjak, I. and Cuello, A.C., Microencapsulated nerve growth factor: effects on the forebrain neurons following devascularizing cortical lesions. Neurosci. Lett., 1992, 140, 71-74.
91. 91. Camarata, P.J., Suryanarayanan, R., Turner, D.A., Parker, R.G. and Ebner, T.J., Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery, 1992, 30, 313-319.
92. 92. Sun, A.M. and O'Shea, G.M., Microencapsulation of living cells: a long-term delivery system. In Advances in Drug Delivery Systems, ed. S.W. Kim and B. Anderson. Elsevier, Amsterdam, 1986, pp. 137-141.
93. 93. Langer, R. and Folkman, J., Polymers for the sustained release of proteins and other macromolecules. Nature, 1976, 263, 797-800.
94. 94. Rhine, W.D., Tsieh, D.S.T. and Langer, R., Polymers for sustained macromolecular release: procedures to fabricate reproducible delivery systems and control release kinetics. J. Pharmacol. Sci., 1980, 69, 265-270.
95. 95. Langer, R. and Moses, M., Biocompatible controlled release polymers for delivery of polypeptides and growth factors. J. Cell Biochem., 1991, 45, 340-345.
96. 96. Murray, J.B., Brown, L., Langer, R. and Klagsbrun, M., A micro sustained release system for epidermal growth factor. In Vitro, 1983, 19, 743-748.
97. 97. Powell, E.M., Sobarzo, R. and Saltzman, W.M., Controlled release of nerve growth factor from a polymeric implant. Brain Res., 1990, 515, 309-311.
98. 98. Langer, R. and Wise, D. (eds), Medical Applications of Controlled Release. CRC Press, Boca Raton, FL, 1984.
99. 99. Langer, R. and Folkman, J., Polymers for the sustained release of proteins and other macromolecules. Nature, 1976, 263, 797-800.
100. 100. Rhine, W., Hsieh, D.S.T. and Langer, R., Polymers for the sustained macromolecule release. J. Pharmacol. Sci., 1981, 69, 265-270.
101. 101. Freese, A., Sabel, B.A., Saltzman, W.M., During, M.J. and Langer, R., Controlled release of dopamine from a polymeric brain implant: in vitro characterization. Exp. Neurol., 1989, 103, 234-238.
102. 102. Lee, E.K.L., Lonsdale, H.K., Baker, R.W., Drioli, E. and Bresnahan, P.A., Transport of steroids in poly(etherurethane) and poly(ethylene vinyl acetate) membranes. J. Membrane Sci., 1985, 24, 125-143.
103. 103. Saltzman, W.M., Pasternak, S.H. and Langer, R., Quantitative image analysis for developing microstructural descriptions of heterogeneous materials. Chem. Eng. Sci., 1987, 42, 1989-2001.
104. 104. During, M.J., Sabel, B.A., Freese, A. et al., Controlled release of dopamine from a polymer brain implant: in vivo characterization. Ann. Neurol., 1989, 25, 351-356.
105. 105. Hoffman, D., Breakefield, X.O., Short, M.P. and Aebischer, P., Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Exp. Neurol., 1993, 122, 100-106.
106. 106. Hoffman, D., Wahlberg, L. and Aebischer, P., NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion. Exp. Neurol., 1990, 110, 39-44.
107. 107. Aebischer, P., Winn, S.R. and Galletti, P.M., Transplantation of neural tissue in polymer capsules. Brain Res., 1988, 448, 364-368.
108. 108. Aebischer, P., Salessiotis, A.N. and Winn, S.R., Basic fibroblast growth factor released from synthetic guidance channels facilitates peripheral nerve regeneration across long nerve gaps. J. Neurosci. Res., 1989, 23, 282-289.
109. 109. Kromer, L.F. and Cornbrooks, C.J., Dissociated Schwann cell/extracellular matrix transplants enhance CNS axonal regeneration. Soc. Neurosci. Abstr., 1989, 15, 1258.
110. 110. Winn, S.R., Hammang, J.P., Emerich, D.F., Lee, A., Palmiter, R.D. and Baetge, E.E., Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons. Proc. Natl. Acad. Sci. USA, 1994, 91, 2324-2328.
111. 111. Balk, S.D., Whitfield, J.F., Youdale, T. and Brown, A.C., Roles of calcium, serum, plasma and folic acid in the control of proliferation of normal and rous sarcoma-virus infected chicken fibroblasts. Proc. Natl. Acad. Sci. USA, 1973, 70, 675-679.
112. 112. Ross, R., Glomset, J., Kariya, B. and Harker, L., A platelet-dependent serum factor that stimulates the proliferation of external smooth muscle cells in vitro. Proc. Natl. Acad. Sci. USA, 1974, 71, 1207-1210.
113. 113. Deuel, T.F., Polypeptide growth factors: roles in normal and abnormal cell growth. Annu. Rev. Cell Biol., 1987, 3, 443-492.
114. 114. Yarden, Y. and Ullrich, A., Growth factor receptor tyrosine kinases. Annu. Rev. Biochem., 1988, 57, 443-478.
115. 115. Morgan, C.J. and Pledger, W.J., In Fibroblast Proliferation in Wound Healing: Biochemical and Clinical Aspects, ed. J.K. Cohen, R.F. Diegelmann and W.J. Lindblad. W.B. Saunders, Philadelphia, 1992, pp. 63-76.
116. 116. Bauer, E.A., Cooper, T.W., Huang, J.S., Altman, J. and Deuel, T.F., Stimulation of in vitro human skin collagenase expression by platelet derived growth factor. Proc. Natl. Acad. Sci. USA, 1985, 82, 4132-4136.
117. 117. Blatti, S.P., Foster, D.N., Ranganathan, G., Moses, H.L. and Getz, M.J., Induction of fibronectin gene transcription and mRNA is a primary response to growth factor stimulation of AKR-2B cells. Proc. Natl. Acad. Sci. USA, 1988, 85, 1119-1123.
118. 118. Clemmons, D.R. and Van Wyk, J.J., Evidence for a functional role of endogenously produced somatomedin-like peptides in the regulation of DNA synthesis in cultured human fibroblasts and porcine smooth muscle cells. J. Clin. Invest., 1985, 75, 1914-1918.
119. 119. Heldin, P., Laurent, T.C. and Heldin, C.H., Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. Biochem. J., 1989, 258, 919-922.
120. 120. Scher, C.D., Shepard, R.C., Antonlades, H.N. and Stiles, C.D., Platelet-derived growth factor and the regulation of the mammalian fibroblast cell cycle. Biochim. Biophys. Acta, 1979, 560, 217-241.
121. 121. Habenicht, A.J.R., Salbech, P., Blattner, C. and Janben-Timmen, U., Platelet-derived growth factor: formation and biological activities. In Growth Factors, Differentiation Factors, and Cytokines, ed. A. Habenicht. Springer, Berlin, 1990, pp. 31-41.
122. 2-macroglobulin. Proc. Natl. Acad. Sci. USA, 1984, 81, 343-346.
123. 123. Gajdusek, C., Carbon, S., Ross, R., Nawroth, P. and Stern, D., Activation of coagulation releases endothelial cell mitogens. J. Cell Biol., 1986, 103, 419-428.
124. 124. McGill, J.J., Strates, B.S. and McGuire, M.H., Osteogenic effects of platelet derived growth factor and microcrystalline hydroxyapatite. J. Bone Min. Res., 1990, 5 (Suppl. 2), 95.
125. 125. McGill, J.J., Strates, B.S. and McGuire, M.H., Stimulation of osteogenesis by PDGF and TGF adsorbed on microcrystals of hydroxyapatite. J. Bone Min. Res., 1991, 6 (Suppl. 1), 503.
126. 126. Mustoe, T.A., Purdy, J., Gramates, P., Deuel, T.F., Thomason, A. and Pierce, G.F., Reversal of impaired wound healing in irradiated rats by platelet-derived growth factor-BB. Am. J. Surg., 1989, 158, 345-350.
127. 127. Mustoe, T.A., Pierce, G.F., Morishima, C. and Deuel, T.F., Growth factor induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J. Clin. Invest., 1991, 87, 694-703.
128. 128. Grotendorst, G.R., Martin, G.R., Pencev, D., Sodek, J. and Harvey, A.K., Stimulation of granulation tissue formation by platelet derived growth factor in normal and diabetic rats. J. Clin. Invest., 1985, 76, 2323-2329.
129. 129. Greenhalgh, D.G., Sprugel, K.H., Murray, M.J. and Ross, R., PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am. J. Pathol., 1990, 136, 1235-1246.
130. 130. Halloran, B.G., So, B.J. and Baxter, B.T., Platelet-derived growth factor is a cofactor in the induction of 1 alpha(I) procollagen expression by transforming growth factor-beta 1 in smooth muscle cells. J. Vasc. Surg., 1996, 23(5), 767-773.
131. 131. Khouri, R.K., Hong, S.P., Deune, E.G. et al., De novo generation of permanent neovascularized soft tissue appendages by platelet-derived growth factor. J. Clin. Invest., 1994, 94(5), 1757-1763.
132. 132. Consigny, P.M., Barry, J.J. and Vitali, N.J., Local delivery of an antiproliferative drug with use of hydrogel-coated angioplasty balloons. J. Vasc. Interventional Radiol., 1994, 5(4), 553-560.
133. 133. Tomaru, T., Yoshimura, A., Inui, K., Nakamura, F., Omata, M. and Uchida, Y., Local delivery of heparin inhibits neointimal hyperplasia in injured rabbit artery. Jap. Heart J., 1995, 36(5), 657-668.
134. 134. Shi, Y., Fard, A., Vermani, P. and Zalewski, A., Transgene expression in the coronary circulation: transcatheter gene delivery. Gene Ther., 1994, 1(6), 408-414.
135. 135. Baird, A. and Walicke, P.A., Fibroblast growth factors. Br. Med. Bull., 1989, 45, 438-452.
136. 136. Lazarou, S.A., Efron, J.E., Shaw, T., Wasserkrug, H.L. and Barbul, A., Fibroblast growth factor inhibits wound collagen synthesis. Surg. Forum, 1989, 40, 627-629.
137. 137. Baird, A., Mormede, P. and Bohlen, P., Immunoreactive fibroblast growth factor in cells of peritoneal exudate suggests its identity with macrophage-derived growth factors. Biochem. Biophys. Res. Commun., 1985, 126, 358-364.
138. 138. Mascarelli, F., Raulais, D., Counis, M.F. and Courtois, Y., Characterization of acidic and basic fibroblast growth factors in brain, retina and vitreous chick embryo. Biochem. Biophys. Res. Commun., 1989, 146, 478-486.
139. 139. Park, C.M. and Hollenberg, M.J., Induction of retinal regneration in vivo by growth factors. Dev. Biol., 1991, 148, 322-333.
140. 140. Whalen, G.F., Shing, Y. and Folkman, J., The fate of intravenously administered bFGF and the effect of heparin. Growth Factors, 1989, 1, 157-164.
141. 141. Edelman, E.R., Mathiowitz, E., Langer, R. and Klagsbrun, M., Controlled and modulated release of basic fibroblast growth factor. Biomaterials, 1991, 12, 619-626.
142. 142. DeBlois, C., Cote, M.-F. and Doillon, C.J., Heparin-fibroblast growth factor-fibrin complex: in vitro and in vivo applications to collagen-based materials. Biomaterials, 1994, 15, 665-672.
143. 143. Shing, Y., Folkman, J., Weisz, P.B., Joullie, M.M. and Erwing, W.R., Affinity of fibroblast growth factors for β-cyclodextrin tetradecasulfate. Analyt. Biochem., 1990, 185, 108-111.
144. 144. Aebischer, P., Salessiotis, A.N. and Winn, S.R., Basic fibroblast growth factor released from synthetic guidance channels facilitates peripheral nerve regeneration across long nerve gaps. J. Neurosci. Res., 1989, 23, 282-289.
145. 145. Urist, M.R. and Dowell, T.A., The inductive substratum for osteogenesis in pellets of particulate bone matrix. Clin. Orthop. Rel. Res., 1969, 61, 61-68.
146. 146. Urist, M.R. and Strates, B.S., Bone morphogenetic protein. J. Dent. Res., 1971, 50, 1392-1406.
147. 147. Huggins, C.B., Wiseman, S. and Reddi, A.H., Transformation of fibroblasts by allogeneic and xenogeneic transplants of demineralized tooth and bone. J. Exp. Med., 1970, 132, 1250-1258.
148. 148. Reddi, A.H. and Huggins, C.B., Influence of transplanted tooth and bone on transformation of fibroblasts. Proc. Soc. Exp. Biol. Med., 1973, 143, 634-637.
149. 149. Syftestad, G.T. and Urist, M.R., Degradation of bone matrix morphogenetic activity by pulverization. Clin. Orthop. Rel. Res., 1979, 141, 281-286.
150. 150. Strates, B.S. and Tideman, J.J., Contribution of osteoinductive and osteoconductive properties of demineralized bone matrix to skeletal repair. Eur. J. Exp. Musculoskel. Res., 1993, 2, 61-67.
151. 151. Urist, M.R., Mikulski, A. and Lietze, A., Solubilized and insolubilized bone morphogenetic protein. Proc. Natl. Acad. Sci. USA, 1979, 76, 1828-1832.
152. 152. Urist, M.R., The search for discovery of bone morphogenetic protein (BMP). In Bone Grafts, Derivatives and Substitutes, ed. M.R. Urist, B.T. O'Conner and R.G. Burwell. Butterworth Heinemann, London, 1994, pp. 315-362.
153. 153. Wozney, J.M., Rosen, V., Celeste, A.J. et al., Novel regulators of bone formation: molecular clones and activities. Science, 1988, 241, 1528-1534.
154. 154. Sampath, T.K., Maliakal, J.C., Hauschka, P.V. et al., Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J. Biol. Chem., 1992, 267, 20352.
155. 155. Joyce, M.E., Roberts, A.B., Sport, M.B. and Bolander, M.E., Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J. Cell Biol., 1990, 110, 2195-2207.
156. 156. Strates, B.S., Kilaghbian, V., Nimni, M.E., McGuire, M.H. and Petty, R.W., Enhanced periosteal osteogenesis induced by rTGFb1 adsorbed on microcrystals of hydroxyapatite. Trans. Orthop. Res. Soc., 1992, 17(2), 591.
157. 157. Nimni, M.E., DiCesare, P., Yazdi, M., Villanueva, J., Strates, B. and Cheung, D.T., Some factors which modulate osteogenesis induced by demineralized bone matrix. In Chemical and Biology of Mineral Tissues, ed. H. Slavkin and P. Price. Excerpta Medica, New York, 1992, pp. 19-28.
158. 158. Urist, M.R., Experimental delivery systems for bone morphogenetic protein. In Encyclopedic Handbook of Biomaterials and Bioengineering, Part A: Materials, Vol. 2, ed. D.L. Wise, D.E. Altobelli, E.R. Schwartz, J.D. Gresser, D.J. Trantolo and M. Yaszemski. Marcel Dekker, Boston, 1994, pp. 1093-1133.
159. 159. Hollinger, J.O. and Leong, K., Poly(α-hydroxy acids): carriers for bone morphogenetic proteins. Biomaterials, 1996, 17(2), 187-194.
160. 160. Muthukumaran, N., Ma, S. and Reddi, A.H., Dose-dependence of and threshold for optimal bone induction by collagenous bone matrix and osteogenin-enriched fraction. Col. Rel. Res., 1988, 8, 433-441.
161. 161. Hammonds, R.G. Jr., Schwall, R., Dudley, A. et al., Bone-inducing activity of mature BMP-2b produced from a hybrid BMP-2a/2b precursor. Molec. Endocrinol., 1991, 5(1), 149-155.
162. 162. Ripamonti, U., Ma, S. and Reddi, A.H., The critical role of geometry of porous hydroxyapatite delivery system in induction of bone by osteogenin, a bone morphogenetic protein. Matrix, 1992, 12, 202-212.
163. 163. Ripamonti, U., Ma, S.-S and Reddi, A.H., Induction of bone incomposites of osteogenin and porous hydroxyapatite in baboons. Plast. Reconstr. Surg., 1992, 89(4), 731-739.
164. 164. Paralkar, V.M., Nandedkar, A.K.N., Pointer, R.H., Kleinman, H.K. and Reddi, A.H., Interactions of osteogenin, a heparin binding bone osteogenic protein with type IV collagen. J. Biol. Chem., 1990, 265, 17281-17284.
165. 165. Katz, R.W., Felthousen, G.C. and Reddi, A.H., Radiation-sterilized insoluble collagenous bone matrix is a functional carrier of osteogenin for bone induction. Calcif. Tiss. Int., 1990, 47, 183-185.
166. 166. Strates, B.S. and Urist, M.R., Origin of the inductive signal in implants of normal and lathyritic bone matrix. Clin. Orthop., 1969, 66, 226-240.
167. 167. DiCesare, P.E., Nimni, M.E., Yazdi, M. and Cheung, D.T., Effects of lathyritic drugs and lathyritic demineralized bone matrix on induced and sustained osteogenesis. J. Orthop. Res., 1994, 12, 395-402.
168. 168. Cordoba, F., Dong, S.-S., Robinson, M., Strates, B.S. and Nimni, M.E., Effect of microcrystalline hydroxy-apatite on bone marrow stromal cell osteogenesis. Trans. Orthop. Res. Soc., 1993, 18, 102.
169. 169. Strates, B.S. and Nimni, M.E., Unpublished results.
170. 170. Randall, J.C., Fullana-Jornet, M.E., Strates, B.S. and Petty, R.W., Modulation enzyme induction in bone marrow stromal cells by an organoapatite. J. Bone Min. Res., 1994, 9 (Suppl. 1), A164.
171. 171. Folkman, J. and Moscona, A., Role of cell shape in growth control. Nature, 1976, 273, 345-349.
172. 172. Ben-Ze'ev, A., Robinson, G.S., Bucher, N.L.R. and Farmer, S.R., Cell-cell and cell-matrix interactions differentially regulate the expression of hepatic and cytoskeletal genes in primary culture of rat hepatocytes. Proc. Natl. Acad. Sci. USA, 1988, 85, 2161-2165.
173. 173. Hay, E.D. (ed.), Cell Biology of the Extracellular Matrix. Plenum, New York, 1981.
174. 174. Ingber, D.E. and Folkman, J., Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J. Cell Biol., 1989, 109, 317-330.
175. 175. Saltzman, W.M., Parsons-Wingerter, P., Leong, K.W. and Lin, S., Fibroblast and hepatocyte behavior on synthetic polymer surfaces. J. Biomed. Mater. Res., 1991, 25, 741-759.
176. 176. Herman, I.M., Crisona, N.J. and Pollard, T.D., Relation between cell activity and the distribution of cytoplasmic actin and myosin. J. Cell Biol., 1991, 90, 84-91.
177. 177. Richards, M., Dahiyat, B.I., Arm, D.M., Brown, P.R. and Leong, K.W., Evaluation of polyphosphates and polyphosphonets as degradable biomaterials. J. Biomed. Mater. Res. 1991, 25, 1151-67.
178. 178. Baier, R.E. and Dutton, R.C., Initial events in interaction of blood with foreign surfaces. J. Biomed. Mater. Res., 1969, 3, 191-206.
179. 179. Anderson, J.M., Bonfield, T.L. and Ziats, N.P., Protein adsorption and cellular adhesion and activation on biomedical polymers. Int. J. Artif. Organs, 1990, 13(6), 375-382.
180. 180. Vroman, L., The life of an artificial device in contact with blood: initial events and their effect on its final state. Bull. N.Y. Acad. Med., 1988, 64, 352-357.
181. 181. Brash, J.L., Scott, C.F., Ten Hove, P., Wojciechowski, P. and Colman, R.W., Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood, 1988, 71, 932-939.
182. 182. Anderson, J.M., Inflammatory response to implants. ASAIO, 1988, 11(2), 101-107.
183. 183. Spilizewski, K.L., Marchant, R.E., Anderson, J.M. and Hiltner, A., In vivo leukocyte interactions with the NHLBI-DTB primary reference materials: polyethylene and silica-free polydimethylsiloxane. Biomaterials, 1987, 8, 12-17.
184. 184. Liu, S.Q., Ito, Y. and Imanishi, Y., Cell growth on immobilized cell-growth factor. 4. Interaction of fibroblast cells with insulin immobilized on poly(methyl methacrylate) membrane. J. Biochem. Biophys. Meth., 1992, 25, 139-148.
185. 185. Ito, Y., Inoue, M., Liu, S.Q. and Imanishi, Y., Cell growth on immobilized cell growth factor. 6. Enhancement of fibroblast cell growth by immobilized insulin and/or fibronectin. J. Biomed. Mater. Res., 1993, 27, 901-907.
186. 186. Ito, Y., Liu, S.Q. and Imanishi, Y., Enhancement of cell growth on growth factor-immobilized polymer film. Biomaterials, 1991, 12, 449-453.
187. 187. Liu, S.Q., Ito, Y. and Imanishi, Y., Cell growth on immobilized cell growth factor. 9. Covalent immobilization of insulin, transferrin, and collagen to enhance growth of bovine endothelial cells. J. Biomed. Mater. Res., 1993, 27, 909-915.
188. 188. Clagett, G.P., Burkel, W.E., Sharefkin, J.B. et al., Platelet reactivity in vivo in dogs with arterial prostheses seeded with endothelial cells. Circulation, 1984, 69, 632-639.
189. 189. Faris, B., Mozzicato, P., Mogayzel, P.J. Jr et al., Effect of protein-hydroxyethyl methacrylate hydrogels on cultured endothelial cells. Exp. Cell Res., 1983, 143, 15-25.
190. 190. Matsuda, T. and Inoue, K., Novel photoreactive surface modification technology for fabricated devices. ASAIO Trans., 1990, 36, 161-164.
191. 191. Matsuda, T., Sugawara, T. and Inoue, K., Two-dimensional cell manipulation technology: an artificial neural circuit based on surface microphotoprocessing. ASAIO J., 1992, 38, M243-M247.
192. 192. Clark, R.A.F., Overview and general considerations of wound repair. In The Molecular and Cellular Biology of Wound Repair, ed. R.A.F. Clark and P.M. Henson. Plenum Press, New York, 1988, pp. 3-33.
193. 193. Roberts, A.B. and Sporn, M.B., Transforming growth factor beta. Adv. Cancer Res., 1988, 51, 107-145.
194. 194. Pierce, G.F., Mustoe, T.A., Altrock, B.W., Deuel, T.F. and Thomason, A., Role of platelet-derived growth factor in wound healing. J. Cell Biochem., 1991, 45, 319-326.
195. 195. Leyen, S.A.-v., Smith, D.J., Bulgrin, J.P., Schafter, I.A. and Eckert, R.L., Delivery of growth factor to wounds using a genetically engineered biological bandage. J. Biomed. Mater. Res., 1993, 27, 1201-1208.
196. 196. Plunkett, M.L. and Hailey, J.A., An in vivo quantitative angiogenesis model using tumor cells entrapped in alginate. Lab. Invest., 1990, 62, 510-517.
197. 197. Downs, E.C., Robertson, N.E., Riss, T.L. and Plunkett, M.L., Calcium alginate beads as a slow-release system for delivering angiogenic molecules in vivo and in vitro. J. Cell Physiol., 1992, 152, 422-429.
198. 198. Buckley, A., Davidson, J.M., Kamerath, C.D., Wolt, T.B. and Woodward, S.C., Sustained release of epidermal growth factor accelerates wound repair. Proc. Natl. Acad. Sci. USA, 1985, 82, 7340-7344.
199. 199. Brown, G.L., Curtsinger, L.J., White, M. et al., Acceleration of tensile strength of incisions treated with EGF and TGF-β. Ann. Surg., 1988, 208, 788-794.
200. 200. Brown, G.L., Curtsinger, L.J., Brightwell, J.R. et al., Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J. Exp. Med., 1986, 163, 1319-1324.
201. 201. Schultz, G.S., White, M., Mitchell, R. et al., Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science, 1987, 235, 350-352.
202. 202. Nanney, L.B., Epidermal and dermal growth factor during wound repair. J. Invest. Dermatol., 1990, 94, 624-629.
203. 203. Brown, G.L., Nanney, L.B., Griffen, J. et al.., Enhancement of wound healing by topical treatment with epidermal growth factor. New Engl. J. Med., 1989, 321, 76-79.
204. 204. Knighton, D.R., Ciresi, K.F., Fiegel, V.D., Austin, L.L. and Butler, E.L., Classification and treatment of chronic non-healing wounds: successful treatment with autologous platelet-derived wound healing factor. Ann. Surg., 1986, 204, 322-330.
205. 205. Schultz, G., Rotatori, D.S. and Clark, W., EGF and TGF-α in wound healing and repair. J. Cell Biochem., 1991, 45, 346-352.
206. 206. Cohen, I.K., Diegelmann, R.F. and Crossland, M.C., Wound care and wound healing. In Principles of Surgery, 6th edn, ed. S.I. Schwartz, G.T. Shires, F.C. Spencer and W.C. Husser. McGraw-Hill, New York, 1994, pp. 279-303.
207. 207. Davidson, J.M., Wound repair. In Inflammation: Basic Principles and Clinical Correlates, 2nd edn, ed. J.I. Gallin, I,M. Goldstein and R. Snyderman. Raven Press, New York, 1992, pp. 809-819.
208. 208. Joyce, M.E., Jingushi, S., Scully, S.P. and Bolander, M.E., Role of growth factors in fracture healing. In Clinical and Experimental Approaches to Dermal and Epidermal Repair: Normal and Chronic Wound Prog. Clin. Biol. Res. 1991, pp. 391-416.
209. 209. Igarashi, A., Okochi, H., Bradham, D.M. and Grotendorst, G.R., Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Molec. Biol. Cell 1993, 4, 637-645.
210. 210. Gartner, M.H., Shearer, J.D., Dominique, M.A., Bereiter, D.F., Mills, C.D. and Caldwell, M.D., Wound fluid amino acid concentrations regulate the effect of epidermal growth factor on fibroblast replication. Surgery, 1991, 110(2), 448-456.
211. 211. Pardee, A.B., G1 events and regulation of cell proliferation. Science, 1989, 246, 603-608.
212. 212. Langer, R., Brown, L. and Edelman, E., Drug and enzyme targeting. Meth. Enzym., 1985, 112, 399.
213. 213. Langer, R. and Moses, M., Biocompatible controlled release polymers for delivery of polypeptides and growth factors. J. Cell Biochem., 1991, 45, 340-345.
214. 214. Leong, K.W., Brott, B.C. and Langer, R., Biodegradable polyanhydride drug-carrier matrices. I. Characterization, degradation, and release characteristics. J. Biomed. Mater. Res., 1985, 19, 941.
215. 215. Gospodarowicz, P., Bialecki, H. and Thakral, T.K., The angiogenic activity of the fibroblast and epidermal growth factor. Exp. Eye Res., 1979, 28, 501.
216. 216. Kull, F.C., Brent, D.A., Parith, I. and Cuatrescasas, P., Chemical identification of a tumor-derived angiogenic factor. Science, 1987, 236, 843.
217. 217. Pliskin, M.E., Induction of neovasculatrization by mitogen-activated spleen cells and their supernatants. Transplantation, 1980, 29, 255.
218. 218. Folkman, J., Weisz, P.B., Jouillie, M.M., Li, W.W. and Ewing, W.Q., Control of angiogenesis with synthetic heparin substitutes. Science, 1989, 243, 1490.
219. 219. Silberstein, G.B. and Daniel, C.W., Reversible inhibition of mammary gland growth by TGF-β. Science, 1987, 237, 291-293.
220. 220. Lucas, P.A., Laurencin, C., Syftestad, G.T. et al., Ectopic induction of cartilage and bone by water soluble proteins from bovine bone using a polyanhydride delivery vehicle. J. Biomed. Mater. Res., 1990, 24, 901.
221. 221. Murray, J., Brown, L. and Langer, R., Controlled release of microquantities of macromolecules. Cancer Drug Delivery, 1984, 1(2), 119-123.
222. 222. Pierschbacher, M.D. and Ruoslahti, E., Cell attachment activity of fibronectin can be duplicated by small synthetic fragment of the molecule. Nature, 1984, 309, 30-33.
223. 223. Kimizuka, F., Ohdate, Y., Kawase, Y. et al., Role of type III homology repeats in cell adhesive function within the cell-binding domain of fibronectin. J. Biol. Chem., 1991, 266, 3045-3051.
224. 224. Hall, F., Wu, L., Liu, L. et al., Expression and renaturation of biologically active human TGF-beta from Escherichia coli inclusion bodies. Transactions of the 41st Annual Meeting, Orthopaedic Research Society, Vol. 20, Section 2, Orlando, FL, 1995.
225. 225. Han, B., Hall, F. and Nimni, M.E., Refolding of a recombinant collagen-targeted TGF-β2 fusion protein expressed in E. coli. Protein Expression and Purification, (in press).
226. 226. Tuan, T.-L., Cheung, D., Wu, L.T. et al., Engineering, expression and renaturation of targeted TGF-beta fusion proteins. Connect. Tiss. Res., 1966, 34, 1-9.
227. 227. Takagi, J., Asai, H. and Saito, Y., A collagen/gelatin-binding decapeptide derived from bovine propolypeptide of von Willebrand factor. Biochemistry, 1992, 31, 8530-8534.
228. 228. Sipes, J.M., Guo, N., Negre, E., Vogel, T., Krutzsch, H.C. and Roberts, D.D., Inhibition of fibronectin binding and fibronectin-mediated cell adhesion to collagen by a peptide from the second type I repeat of thrombospondin. J. Cell Biol., 1993, 121(2), 469-477.